Ypsomed & Adval in mold-making deal:
This article was originally published in Clinica
Burgdorf-based Ypsomed has agreed to use the injection molding technology of fellow Swiss company Adval Tech Holding in the production of its injection pen and pen needle range. Ypsomed CEO Richard Fritschi said his company could reduce lead times and better standardise the product range by incorporating the Niederwangen company's expertise. Subassembly and components company Adval has been targeting penetration of selected new markets, including medtech and pharma. Its CEO, Jean-Claude Philipona, said the deal would result in added value throughout the entire value chain.